Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Purinethol (correction)

Executive Summary

In a story on Purinethol (6-mercaptopurine) labeling, "The Pink Sheet" referred to the leukemia drug as a GlaxoSmithKline product ("The Pink Sheet" July 21, 2003, p. 33). Teva received rights to Purinethol July 1 as part of its patent settlement with GSK regarding generics of Relafen (nabumetone) (1"The Pink Sheet" May 5, 2003, In Brief)...

You may also be interested in...



Teva/GSK settle Relafen litigation

All patent litigation between Teva and GSK regarding generics of Relafen (nabumetone) has been settled, Teva says April 30. Teva entered generic nabumetone market in August 2001 with 500 mg and 750 mg tablets following successful Boston federal court challenge of GSK patent (1"The Pink Sheet" Aug. 20, 2001, p. 14)...

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.

Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds

First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.

UsernamePublicRestriction

Register

PS042218

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel